Bargou R et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974–977
Clinical data indicate a role for cytotoxic T lymphocytes in the control of tumor growth. However, immunotherapy strategies that induce antitumor T-cell responses have been characterized by low response rates. Bargou et al. assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non-Hodgkin lymphoma who relapsed after standard treatments.
This ongoing study has so far included 38 patients (with hematologic malignancies such as follicular lymphoma, mantle-cell lymphoma and chronic lymphocytic leukemia), who received blinatumomab for 4–8 weeks at doses of 0.0005–0.06 mg/m2 daily. Target cells that expressed CD19 were depleted in the blood of patients who received ≥0.005 mg/m2 of the drug; this decline was shown to be caused by apoptosis. Among 38 patients, 4 complete and 7 partial tumor regressions occurred in patients who received ≥0.015 mg/m2 blinatumomab, which suggests that the response is dose-dependent. Tumor regression was observed in all 7 patients treated with 0.06 mg/m2 blinatumomab. The majority of tumor shrinkage occurred within the first 4 weeks of therapy, and no relapse had been observed at the date of publication in patients treated with 0.03 mg/m2 and 0.06 mg/m2 blinatumomab. In patients who received blinatumomab doses ≥0.015 mg/m2, tumor-cell depletion was observed in the blood, lymph nodes, spleen, bone marrow and liver.
These results suggest that blinatumomab is a promising new anticancer agent. Clinical trials that investigate the efficacy of bispecific antibodies, in hematologic and solid tumors, are warranted.
Rights and permissions
About this article
Cite this article
Novel bispecific antibody causes tumor regression in patients with non-Hodgkin lymphoma. Nat Rev Clin Oncol 5, 684 (2008). https://doi.org/10.1038/ncponc1245
Issue Date:
DOI: https://doi.org/10.1038/ncponc1245